Hypercholesterolaemia

Hypercholesterolaemia is most commonly, but not exclusively, defined as elevated levels of low-density lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (HDL-C); an alternative term is dyslipidaemia, which encompasses elevated triglycerides, low levels of HDL-C, and qualitative lipid abnormalities.

Hypercholesterolaemia is an important risk factor for atherosclerotic cardiovascular disease, including cerebrovascular disease, coronary heart disease, and peripheral arterial disease; it is usually symptomatically quiescent until significant atherosclerosis has developed.

Complications of hypercholesterolaemia and atherosclerosis include myocardial infarction, ischaemic cardiomyopathy, sudden cardiac death, ischaemic stroke, erectile dysfunction, claudication, and acute limb ischaemia.

Risk factors for secondary hypercholesterolaemia in industrialised populations include a sedentary lifestyle and a diet characterised by the excessive consumption of saturated fats, trans-fatty acids, and cholesterol. Other associations include diabetes, excess body weight mainly in the abdominal region, hypothyroidism, nephrotic syndrome, and cholestatic liver disease. Low HDL-C levels are associated with smoking and abdominal obesity.

It is diagnosed by a lipid profile, consisting of measurements of total cholesterol, LDL-C (estimated or direct), HDL-C, and triglycerides. Non-HDL-C is calculated by the subtraction of HDL-C from total cholesterol.

Hypercholesterolaemia is treated with lifestyle modifications such as dietary changes, exercise, and smoking cessation, as well as pharmacological intervention with statin therapy, and selective use of the cholesterol absorption inhibitor ezetimibe or a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor.

Hypercholesterolaemia, an elevation of total cholesterol (TC) and/or low-density lipoprotein cholesterol (LDL-C) or non-high-density lipoprotein cholesterol (HDL-C) (defined as the subtraction of HDL-C from TC) in the blood, is also often referred to as dyslipidaemia, to encompass the fact that it might be accompanied by a decrease in HDL-C, an increase in triglycerides, or qualitative lipid abnormalities. Dyslipidaemia is classified as serum TC, LDL-C, triglycerides, apolipoprotein B, or lipoprotein(a) concentrations above the 90th percentile, or HDL-C or apolipoprotein A-I concentrations below the 10th percentile for the general population. However, these classic percentile cut-off points should not be used too rigidly in defining dyslipidaemia. For example, evidence suggests that lipoprotein(a) ≥80th percentile is abnormal and linked to elevated cardiovascular risk.[1]Verbeek R, Hoogeveen RM, Langsted A, et al. Cardiovascular disease risk associated with elevated lipoprotein(a) attenuates at low low-density lipoprotein cholesterol levels in a primary prevention setting. Eur Heart J. 2018 Jul 14;39(27):2589-96. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6287703/ http://www.ncbi.nlm.nih.gov/pubmed/29931232?tool=bestpractice.com